Portland, Oregon
CNS clinical trials in Portland, OR
47 CNS studies are recruiting participants at sites in Portland as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Portland at a glance
- 47 studies are recruiting at a site in Portland.
- By phase: Phase 1/2 (2), Phase 2 (4), Phase 2/3 (1), Phase 3 (19), Phase 4 (5), No phase (10), Observational (6). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (25), university, hospital or other (16), government (6).
- By research area: Parkinson's Disease (15), Depression (12), Migraine (7), ADHD (5), Epilepsy (5), Multiple Sclerosis (3).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Portland
Basic details from each study's public record (the 30 most recently updated of 47). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- Summit Headlands (Headlands Research)
- Registry record
- NCT07226661 · updated
Center M Randomized Trial
- No phase
- Ages 18 and older
- Female participants
- Sponsor
- Oregon Health and Science University
- Study site
- Oregon Health & Science University
- Registry record
- NCT07304895 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Kaiser Permanente Northwest · Providence Portland Medical Center · Providence Saint Vincent Medical Center
- Registry record
- NCT06748222 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Summit Headlands
- Registry record
- NCT07412756 · updated
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- VA Portland Health Care System, Portland, OR
- Registry record
- NCT07226232 · updated
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07484217 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Portland, OR on ClinicalTrials.gov.
ADHD studies recruiting in Portland
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
- Phase 3
- Ages 6 to 11
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717879 · updated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717892 · updated
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- Summit Research Network
- Registry record
- NCT07759154 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Portland, OR on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Portland
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
- Phase 2
- Ages 50 to 80
- All sexes
- Sponsor
- Yale University
- Study site
- Oregon Health & Science University
- Registry record
- NCT06996652 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Oregon Health and Science University
- Registry record
- NCT07174310 · updated
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- Phase 3
- Ages 45 to 75
- All sexes
- Sponsor
- BlueRock Therapeutics
- Study site
- OHSU Neurology Clinic, South Waterfront
- Registry record
- NCT06944522 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Oregon Health & Science University (OHSU)
- Registry record
- NCT06680830 · updated
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
- Phase 2/3
- Ages 40 to 80
- All sexes
- Sponsor
- Biohaven Therapeutics Ltd.
- Registry record
- NCT06976268 · updated
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Providence Portland Medical Center ( Site 0044) · Providence St. Vincent Medical Center ( Site 0081)
- Registry record
- NCT06312176 · updated
Parkinson's Foundation PD GENEration Genetic Registry
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Parkinson's Foundation
- Study site
- Oregon Health and Science University
- Registry record
- NCT04994015 · updated
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- Phase 4
- Ages 40 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- VA Portland Health Care System, Portland, OR
- Registry record
- NCT04373317 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Portland, OR on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Portland
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Providence Neurological Services West
- Registry record
- NCT06846281 · updated
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- Phase 3
- Ages 18 to 55
- All sexes
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study site
- Multiple Sclerosis Center, Oregon Health & Science University
- Registry record
- NCT04047628 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Portland, OR on ClinicalTrials.gov.
Epilepsy studies recruiting in Portland
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- VA Portland Health Care System, Portland, OR
- Registry record
- NCT04419272 · updated
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Providence Neurological Specialities
- Registry record
- NCT05716100 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study site
- Oregon Health and Science University
- Registry record
- NCT05135091 · updated
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Encoded Therapeutics
- Study site
- Oregon Health and Science University (OHSU)
- Registry record
- NCT05419492 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Portland, OR on ClinicalTrials.gov.
Migraine studies recruiting in Portland
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Advanced Research Institute
- Registry record
- NCT06972056 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Advanced Research Institute - Portland · Summit Research Network
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Advanced Research Institute-Portland · Summit Research Network
- Registry record
- NCT07674654 · updated
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study sites
- Providence Neuroscience Institute - Research Coordinator's Office · Providence St. Vincent Medical Center
- Registry record
- NCT04649242 · updated
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study sites
- Providence Neuroscience Institute: Research Coordinators' Office · Providence Pediatric Specialty Clinic
- Registry record
- NCT04743141 · updated
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Providence Brain and Spine Institute /ID# 231607
- Registry record
- NCT05125302 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Portland, OR on ClinicalTrials.gov.
Ask about studies near Portland
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections